Cemiplimab

證據等級: L5

預測適應症: 10 個

Cemiplimab: From Cutaneous Squamous Cell Carcinoma to Gallbladder Adenosquamous Carcinoma

One-Sentence Summary

Cemiplimab (Libtayo®) is a fully human anti-PD-1 monoclonal antibody (immune checkpoint inhibitor) approved globally for cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC), though it currently holds no marketing authorisation in Denmark. The TxGNN model predicts it may be effective for gallbladder adenosquamous carcinoma as the highest-ranked indication, supported by 0 clinical trials and 0 publications for this specific subtype. This is a multi-indication evaluation (5 unique oncological predictions), ranging from L3 evidence (external ear basal cell carcinoma, which aligns with cemiplimab’s globally approved BCC indication) to L5 model-only predictions; overall recommended decisions vary from Hold to Proceed with Guardrails depending on the predicted indication.

Quick Overview

Item	Content
Original Indication	Not registered in Denmark; globally approved for cutaneous squamous cell carcinoma (cSCC), BCC, NSCLC, and cervical cancer (Libtayo® / Regeneron–Sanofi)
Predicted New Indication (Rank 1)	Gallbladder adenosquamous carcinoma
TxGNN Prediction Score	99.99%
Evidence Level (Rank 1)	L5 — Model prediction only; no supporting studies
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision (Rank 1)	Hold

All Predicted Indications — Overview

This evaluation is a multi-indication candidate (ID: TW-DB14707-multi). The five unique predicted indications are summarised below (duplicate rank entries in the source data have been consolidated):

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommended Decision
1	Gallbladder adenosquamous carcinoma	99.99%	L5	Hold
3	Glottis squamous cell carcinoma	99.99%	L4	Research Question
5	Rectal cloacogenic carcinoma	99.99%	L5	Hold
7	External ear basal cell carcinoma	99.99%	L3	Proceed with Guardrails
9	Adenosquamous prostate carcinoma	99.99%	L5	Hold

Key clinical finding: The highest-evidence prediction (external ear BCC, L3) corresponds directly to cemiplimab’s globally approved BCC indication (EMPOWER-BCC-1, FDA approval 2021; EMA approval). The “Not marketed” status in Denmark most likely reflects a local market access gap rather than absence of clinical evidence or regulatory approval.

Why is This Prediction Reasonable?

Mechanism of Action

The Evidence Pack does not contain mechanistic action (MOA) data for cemiplimab. Based on published information, cemiplimab is a fully human IgG4 monoclonal antibody that binds specifically to the programmed cell death receptor 1 (PD-1) on T lymphocytes, blocking its interaction with PD-L1 and PD-L2 on tumour cells and antigen-presenting cells. This blockade relieves PD-1-mediated suppression of anti-tumour T-cell activity, restoring immune-mediated cytotoxicity within the tumour microenvironment. Cemiplimab is classified as an immune checkpoint inhibitor (ICI) and belongs to the anti-PD-1 immunotherapy category — not a conventional cytotoxic agent.

Rank 1 — Gallbladder Adenosquamous Carcinoma (L5, Hold)

Gallbladder adenosquamous carcinoma is a rare mixed histological subtype containing both glandular (adenocarcinoma) and squamous cell carcinoma components. The squamous cell component theoretically may express PD-L1, providing a mechanistic rationale for PD-1 blockade. Indirect support comes from the structurally related checkpoint inhibitor durvalumab, which demonstrated a statistically significant overall survival benefit in biliary tract cancer in the TOPAZ-1 Phase 3 trial. However, cemiplimab has no published clinical data in this specific rare subtype, and the TxGNN high score most likely reflects broad class-level inference from the squamous cell carcinoma category rather than indication-specific mechanistic support. This prediction requires substantially more evidence before clinical consideration.

Most Evidence-Supported — External Ear Basal Cell Carcinoma (L3, Proceed with Guardrails)

Basal cell carcinoma of the external ear is an anatomical subtype of BCC characterised by high surgical complexity due to proximity to the facial nerve and parotid gland, making curative resection frequently impractical. Cemiplimab received FDA approval in February 2021 for locally advanced and metastatic BCC in patients who are not candidates for curative surgery or curative radiation therapy after progression on a Hedgehog pathway inhibitor (vismodegib/sonidegib), supported by the EMPOWER-BCC-1 Phase 2 programme; EMA subsequently granted centralised authorisation. External ear BCC is precisely the clinical scenario for which this approval was designed. One published case report (PMID 34157152) documents a durable, lasting response following cemiplimab discontinuation in a patient with locally advanced BCC, mechanistically consistent with the approved indication. This is not a classic drug repurposing situation; rather, it represents a market access gap in Denmark for an already globally validated indication.

Glottis Squamous Cell Carcinoma (L4, Research Question)

Glottic squamous cell carcinoma falls within the head and neck squamous cell carcinoma (HNSCC) spectrum. Cemiplimab’s EMPOWER-HN clinical programme has generated Phase 2/3 data across HNSCC tumour sites, including laryngeal subgroups. Glottic SCC shares key immunotherapy biomarker profiles with other HNSCC subsites — PD-L1 expression, tumour mutational burden (TMB), and HPV status — making the mechanistic analogy compelling. However, glottis-specific subgroup data are not independently available, and the evidence relies on indirect extrapolation from broader HNSCC datasets.

Clinical Trial Evidence

No clinical trials were identified for any of the 5 predicted indications in this evaluation (gallbladder adenosquamous carcinoma, glottis SCC, rectal cloacogenic carcinoma, external ear BCC, or adenosquamous prostate carcinoma).

Note for clinical context: Cemiplimab has extensive Phase 2/3 trial data in related broader tumour categories (EMPOWER-BCC-1 for BCC, EMPOWER-HN for HNSCC, EMPOWER-Lung 1 and 3 for NSCLC), which underpin its global regulatory approvals. These are not listed here as they were not retrieved in the evidence collection queries for the specific predicted indications above.

Literature Evidence

Literature evidence was identified only for external ear basal cell carcinoma (rank 7):

PMID	Year	Type	Journal	Key Findings
34157152	2021	Case Report	Clinical and Experimental Dermatology	Documents a lasting clinical response in a patient with locally advanced BCC following discontinuation of cemiplimab, supporting the durability of anti-PD-1 immune response in BCC and the potential for sustained remission after treatment cessation

No literature was identified for gallbladder adenosquamous carcinoma, glottis SCC, rectal cloacogenic carcinoma, or adenosquamous prostate carcinoma with cemiplimab.

Denmark Market Information

Cemiplimab currently holds no marketing authorisations in Denmark (Lægemiddelstyrelsen), with a total of 0 registered products.

However, cemiplimab (Libtayo®) holds a valid EMA centralised marketing authorisation covering the following indications — accessible in principle to Danish patients via Named Patient Programme (NPP) or comparable access pathways:

Authorisation	Product Name	Dosage Form	Approved Indication
EU/1/19/1376 (EMA)	Libtayo®	Concentrate for solution for infusion (350 mg/7 mL)	Cutaneous squamous cell carcinoma (cSCC) — locally advanced or metastatic; Basal cell carcinoma (BCC) — locally advanced or metastatic, after Hedgehog pathway inhibitor failure; Non-small cell lung carcinoma (NSCLC) — first-line, in combination with platinum-based chemotherapy; Cervical cancer — recurrent or …

Danish prescribers seeking access for eligible patients should consult Lægemiddelstyrelsen regarding NPP/compassionate use procedures under European Regulation (EC) No 726/2004 Article 83.

Cytotoxicity

Cemiplimab is an antineoplastic agent targeting solid malignancies. The following classification applies:

Item	Content
Cytotoxicity Classification	Immunotherapy — Immune checkpoint inhibitor (fully human anti-PD-1 IgG4 monoclonal antibody); not a conventional cytotoxic agent
Myelosuppression Risk	Low compared to conventional chemotherapy; however, immune-related haematological adverse events (immune thrombocytopaenia, haemolytic anaemia, aplastic anaemia) can occur and require monitoring
Emetogenicity Classification	Minimal; immunotherapy agents are not associated with direct emetogenicity
Monitoring Items	CBC with differential, liver function tests (ALT, AST, bilirubin), thyroid function (TSH, free T4), morning cortisol/ACTH (for immune-mediated adrenal insufficiency), renal function (creatinine), blood glucose (immune-mediated type 1 diabetes mellitus), and clinical assessment for pneumonitis and colitis at each visit
Handling Protection	Standard biosafety precautions for monoclonal antibody preparations; conventional cytotoxic handling regulations do not apply, but institutional biological medicine safety protocols should be followed

Safety Considerations

Please refer to the EMA-approved Summary of Product Characteristics (SmPC) for Libtayo® for complete safety information, available via the European Medicines Agency (EMA) EPAR database.

Key considerations relevant to Danish prescribers:

Immune-related adverse events (irAEs): As a PD-1 checkpoint inhibitor, cemiplimab carries risk of immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies (hypothyroidism, hyperthyroidism, adrenal insufficiency, type 1 diabetes mellitus), nephritis, and dermatitis. Severe irAEs (Grade 3–4) require treatment suspension and high-dose systemic corticosteroids; specialist referral (pulmonology, gastroenterology, endocrinology) is recommended.
Drug Interactions: No DDI data were retrieved in this evaluation. Note that corticosteroids used to manage irAEs may potentially attenuate immunotherapy efficacy; the timing and dose of immunosuppressive therapy require careful clinical judgement and should follow published irAE management guidelines (e.g., ESMO/ASCO guidelines).

Conclusion and Next Steps

Primary Prediction: Gallbladder Adenosquamous Carcinoma

Decision: Hold

Rationale: Gallbladder adenosquamous carcinoma is an ultra-rare tumour subtype with no identified clinical trial or published data for cemiplimab. The TxGNN high score reflects model-level generalisation from the squamous cell carcinoma category and does not provide sufficient clinical basis for use outside a formal investigational framework.

To proceed, the following is needed:

Biomarker profiling (PD-L1 expression by IHC, TMB, MSI/MMR status) of gallbladder adenosquamous carcinoma tissue samples to confirm immunotherapy-susceptible biology
Consideration for basket trial enrolment (tumour-agnostic PD-1 inhibitor programmes covering rare biliary/GI cancers)
Multidisciplinary tumour board review in a specialised hepatobiliary oncology centre
Review of emerging data from durvalumab (TOPAZ-1) in biliary tract cancer for indirect mechanistic benchmarking

Most Clinically Actionable Prediction: External Ear Basal Cell Carcinoma

Decision: Proceed with Guardrails

Rationale: External ear BCC falls squarely within cemiplimab’s EMA-approved indication for locally advanced/metastatic BCC after Hedgehog pathway inhibitor failure. The “not marketed” status in Denmark appears to represent a market access gap rather than absence of validated evidence, making this the most actionable finding in this evaluation.